AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21903745
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy with cisplatin (100 mg/m2) and TRT (63 Gy delivered as once-daily fractions beginning on day 1)
Trial: 21903745
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy with cisplatin (50 mg/m2 on days 1, 8, 29, and 36) and oral etoposide (50 mg twice daily for 10 weeks on days 1, 2, 5, and 6) with TRT (69.6 Gy delivered as 1.2 Gy twice-daily fractions beginning on day 1)
Trial: 8901660
Drug: 100 mg/d
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/d aspirin
Trial: 16676655
Drug: Midodrine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (10 mg, orally) administered after landing approximately 1 h before testing
Trial: 15316165
Drug: 1 mg/day
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/day oral finasteride for 12 months
Trial: 15316165
Drug: 5% topical
RxNorm normalized name: BP 5% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% topical minoxidil solution applied twice daily for 12 months
Trial: 3838401
Drug: molsidomine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: molsidomine (2 mg intravenously)
Trial: 3838401
Drug: isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: isosorbide dinitrate (ISDN) (5 mg sublingually)
Trial: 2906956
Drug: nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine (20 mg sublingually)
Trial: 27287235
Drug: Dolutegravir monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir monotherapy (50 mg/day)
Trial: 24933430
Drug: 6% CHO‐electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% CHO‐electrolyte solution
Trial: 24933430
Drug: Electrolyte (placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolyte (placebo) solution
Trial: 26051481
Drug: Enzyme Replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme Replacement Therapy (ERT)
Trial: 18157595
Drug: Symphytum herb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symphytum herb extract cream (10% active ingredient)
Trial: 16185409
Drug: Negative charge
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Negative charge aerosol (NCA) treatment for 1.5 hours, 1-2 times a day, from 6 postburn hours to 2 postburn days.
Trial: 16185409
Drug: Negative charge
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Negative charge aerosol (NCA) treatment in self control group with sterile schissel coverage.
Trial: 16185409
Drug: Negative charge
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Negative charge aerosol (NCA) treatment in trial group.
Trial: 16185409
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment in control group.
Trial: 16185409
Drug: Pathological examination
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pathological examination in rats treated with conventional treatment.
Trial: 14640055
Drug: Cholinesterase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinesterase inhibitors
Trial: 320995
Drug: Clobetasone butyrate
RxNorm normalized name: clobetasone butyrate
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Clobetasone butyrate ointment
Trial: 320995
Drug: Flurandrenolone ointment
RxNorm normalized name: Flurandrenolone
DrugBank: Flurandrenolide acetate (DB14673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurandrenolone ointment
Trial: 30205315
Drug: Chlorella supplementation
RxNorm normalized name: Chlorella emersonii extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorella supplementation (1500 mg/day for 8 weeks)
Trial: 30407136
Drug: Hydrocortisone and
RxNorm normalized name: hydrocortisone and mydriatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone and Yohimbine (both drugs)
Trial: 29056008
Drug: Peg‐IFN‐α‐2b (Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐IFN‐α‐2b (Y shape, 40 kD) injection (180 μg/week)
Trial: 18042501
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor (PI)
Trial: 23809140
Drug: Non-nucleosidic reverse
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-nucleosidic reverse transcriptase inhibitor (NNRTI)
Trial: 17014541
Drug: Xeno III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xeno III (self-etching priming agent)
Trial: 17165277
Drug: Montelukast, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast, 10 mg/d
Trial: 17336941
Drug: Naltrexone 0
RxNorm normalized name: MORPHINE 20MG/NALTREXONE 0.8MG SA CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 0 mg/day (placebo)
Trial: 9306297
Drug: Progressive relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive relaxation and visualization treatment (6 hour-long sessions over 3 weeks)
Trial: 9306297
Drug: Psychoeducational addiction
RxNorm normalized name: DRUGS USED IN ADDICTIVE DISORDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational addiction treatment group
Trial: 8320604
Drug: Synthetic surfactant
RxNorm normalized name: Synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue
DrugBank: CHF5633 (DB18696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic surfactant administration
Trial: 3578725
Drug: Droperidol 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.1 mg/kg with fentanyl 3.0 micrograms/kg (group 2)
Trial: 30730774
Drug: Collaborative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative and Proactive Solutions (CPS)
Trial: 25149412
Drug: Oxytocin (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (24 IU intranasal single dose)
Trial: 22234020
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 mcg/kg)
Trial: 9024174
Drug: DuP 532
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DuP 532 (200 mg)
Trial: 9024174
Drug: DuP 532
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DuP 532 and Losartan (24 hours after dosing)
Trial: 3477986
Drug: Local oestriol
RxNorm normalized name: Oestriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local oestriol treatment for 3 weeks
Trial: 3477986
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (similar ointment without oestriol) for 3 weeks
Trial: 30631386
Drug: FNB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FNB with 15 ml of lidocaine with epinephrine (300 mg) and 3 ml of MgS 15% (450 mg)
Trial: 30631386
Drug: FNB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FNB with 15 ml of lidocaine with epinephrine (300 mg) and 3 ml of normal saline solution
Trial: 17917738
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) 1.25 mg/0.05 ml, three injections at 6-week intervals
Trial: 17917738
Drug: Combined intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravitreal bevacizumab (IVB) and triamcinolone (IVT) 1.25 mg/0.05 ml and 2 mg/0.05 ml respectively, followed by two injections of IVB at 6-week intervals
Trial: 23924918
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection (control group)
Trial: 29873004
Drug: Higher starting
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Higher starting dose of basal insulin glargine (0.3 U/kg)
Trial: 29873004
Drug: Standard starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard starting dose of basal insulin glargine (0.2 U/kg)
Trial: 27346552
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral vitamin K (LDVK) 150 mcg daily for six months
Trial: 27346552
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral vitamin K (LDVK)
Trial: 22167126
Drug: Overnight modest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overnight modest hyperinsulinaemia (average ≈ 286 pmol/l)
Trial: 22167126
Drug: Marked hyperinsulinaemia
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marked hyperinsulinaemia during the clamp (average steady-state insulin ≈ 900 pmol/l)
Trial: 17484484
Drug: 80 watt
RxNorm normalized name: Silver wattle pollen
DrugBank: Acacia dealbata pollen (DB15504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 watt KTP-laser treatment for small adenomas
Trial: 17484484
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of KTP-laser and TUR-P for great adenomas
Trial: 31111235
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment for primary prevention of ASCVD in patients older than 75 years
Trial: 31111235
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment for secondary prevention of ASCVD in patients older than 75 years
Trial: 31111235
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment initiation before 75-80 years
Trial: 31111235
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of statin treatment when palliative treatment starts
Trial: 23578453
Drug: Multimodal-antiemetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal-antiemetic therapy (group M) including target-controlled infusion of propofol and remifentanil, prophylactic dexamethasone 10 mg, tropisetron 4 mg, and parecoxib sodium 40 mg 30 minutes before the end of surgery
Trial: 23578453
Drug: Ondansetron control
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron control (group C) including sevoflurane and 50% nitrous oxide, prophylactic ondansetron 4 mg 30 minutes before the end of surgery
Trial: 19799471
Drug: Duodenal levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Duodenal levodopa infusion (DLI)
Trial: 7104182
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral therapy
Trial: 16945766
Drug: Adjuvant vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant vinorelbine plus cisplatin (30 mg/m² vinorelbine plus 100 mg/m² cisplatin)
Trial: 10394407
Drug: 3-D conformal
RxNorm normalized name: trans-resveratrol 3-β-D-glucoside
DrugBank: Polydatin (DB11263)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-D conformal photon radiotherapy at a dose of 66 Gy
Trial: 8871870
Drug: Interferon-alpha 2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 2b (5 MU m-2, then 3 MU m-2 three times weekly for 12 or 24 months)
Trial: 1996795
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g milk chocolate‐charcoal mixture
Trial: 1996795
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g SuperChar Liquid
Trial: 1996795
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g Actidose Aqua activated charcoal
Trial: 6350078
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus insulin
Trial: 6350078
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and sulphonylurea therapy
Trial: 22081522
Drug: Asacol 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asacol 2.4 g once daily (OD)
Trial: 22081522
Drug: Asacol 800
RxNorm normalized name: mesalamine 800 MG [Asacol]
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asacol 800 mg three times daily (TDS)
Trial: 20206793
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of oral piroxicam 20 mg
Trial: 15924753
Drug: Surfactant (Curosurf)
RxNorm normalized name: Curosurf
DrugBank: Poractant alfa (DB09113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surfactant (Curosurf) 200 mg/kg initial dose, repeated doses of 200, 100, and 100 mg/kg at 6-12 hour intervals, maximum of four doses if OI deteriorated by > 2 from baseline
Trial: 12813474
Drug: Oral hydrocortisone
RxNorm normalized name: hydrocortisone Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydrocortisone 50 mg
Trial: 12813474
Drug: Corticosteroid synthesis
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid synthesis inhibitor metyrapone 1500 mg orally
Trial: 12813474
Drug: Methamphetamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methamphetamine 0.5 mg/kg
Trial: 10585796
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of co-trimoxazole
Trial: 10585796
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of co-trimoxazole
Trial: 1654967
Drug: Pipecuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipecuronium 0.1 mg kg‐1
Trial: 2877682
Drug: Tubocurarine 0.5
RxNorm normalized name: tubocurarine 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tubocurarine 0.5 mg kg‐1
Trial: 31037449
Drug: Usual dose
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual dose rabeprazole (10 mg/day) + HST (7.5 g/day)
Trial: 31037449
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose rabeprazole (20 mg/day)
Trial: 21993580
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (estradiol associated with trimegestone)
Trial: 19447518
Drug: Sequential prediction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential prediction algorithm based on viral kinetics at weeks 2 and 4
Trial: 17901791
Drug: Comparator (amoxicillin/clavulanate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator (amoxicillin/clavulanate, ceftriaxone, clarithromycin, or erythromycin lactobinate)
Trial: 8078953
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg paroxetine per day
Trial: 2688529
Drug: Iopromide 370
RxNorm normalized name: IOPROMIDE 370mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopromide 370 mgI/ml
Trial: 29959901
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives 1 (20μg EE/150μg desogestrel)
Trial: 29959901
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives 2 (30μg EE/3mg drospirenone)
Trial: 29959901
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives 1 and 2
Trial: 26628523
Drug: Pain exposure
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain exposure physical therapy (PEPT)
Trial: 23789215
Drug: Acupoint-combination stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint-combination stimulation group
Trial: 21671752
Drug: DPI-C (dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPI-C (dry powder inhaler with ∼10% less of each drug per metered dose)
Trial: 21671752
Drug: DPI-A (Advair
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPI-A (Advair Diskus®, GlaxoSmithKline, delivering 100 μg fluticasone propionate and 50 μg salmeterol)
Trial: 11015169
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors)
Trial: 8730243
Drug: Lornoxicam 8
RxNorm normalized name: lornoxicam 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 8 mg b.d.
Trial: 6231893
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg b.d.
Trial: 1382255
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy and radiotherapy (3 courses of chemotherapy with cisplatin 100 mg/m2, day 1 and etoposide 125 mg/m2 i.v., day 1; 250 mg/m2 p.o., day 2-3, followed by radiotherapy 4,000 cGy/20 fractions/4 weeks)
Trial: 2580182
Drug: Captopril +
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril + Propranolol + Diuretic
Trial: 30046837
Drug: MDCO-216 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDCO-216 (20 mg/kg weekly for 5 weeks)
Trial: 22123525
Drug: Dexpanthenol cream
RxNorm normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexpanthenol cream once daily (B)
Trial: 22123525
Drug: wIRA irradiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: wIRA irradiation for 30 min once daily together with dexpanthenol cream once daily (D)
Trial: 22123525
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (A)
Trial: 22123525
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (B-D)
Trial: 15855263
Drug: L-T(4) replacement
RxNorm normalized name: L-3972-T
DrugBank: L-3972-T (DB17441)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-T(4) replacement
Trial: 12421103
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 to 600mg followed by oral misoprostol 0.4 to 0.6mg or vaginal gemeprost 1.0mg/misoprostol 0.8mg
Trial: 2122251
Drug: Heparin (5000-unit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (5000-unit bolus followed by continuous intravenous heparin)
Trial: 2122251
Drug: Aspirin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (80 mg daily oral)
Trial: 22157279
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 50 mg BID
Trial: 22157279
Drug: Naproxen 300
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 300 mg BID
Trial: 22157279
Drug: Glucosamine hydrochloride
RxNorm normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine hydrochloride 750 mg BID
Trial: 17569792
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of eccentric training and AirHeel brace
Trial: 15788347
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy aimed at restoring dynamic stabilizing mechanisms and muscle co‐ordination at the shoulder
Trial: 15788347
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of physical modalities and range of motion exercises
Trial: 1790251
Drug: Prophylactic indomethacin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic indomethacin, 0.2 mg/kg, i.v. 24 h after birth
Trial: 6759136
Drug: Carprofen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carprofen (100 mg in the morning plus 200 mg in the evening)
Trial: 6759136
Drug: Carprofen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carprofen (100 mg 3 times daily)
Trial: 31284844
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual daily lifestyle)
Trial: 22786569
Drug: Losartan/HCTZ (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan/HCTZ (50 mg losartan + 12.5 mg hydrochlorothiazide per day)
Trial: 22786569
Drug: Maximal-dose ARB
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal-dose ARB